Warrants (Details) - $ / shares |
12 Months Ended | |
---|---|---|
Jan. 31, 2022 |
Jan. 31, 2021 |
|
Warrants | ||
Warrants Outstanding Shares, Beginning | 2,675,000 | 3,000,000 |
Cancelled, Shares | (350,000) | (250,000) |
Exercised, Shares | (190,000) | (75,000) |
Granted, Shares | 2,856,000 | 0 |
Warrants Outstanding Shares, Ending | 4,991,000 | 2,675,000 |
Warrants Outstanding Weighted Average Conversion Price, Beginning | $ 1.00 | $ 1.00 |
Weighted Average Conversion Price, Cancelled | 3.58 | 1.00 |
Weighted Average Conversion Price, Exercised | 1.32 | 1.00 |
Weighted Average Conversion Price, Granted | 4.54 | 0 |
Warrants Outstanding Weighted Average Conversion Price, Ending | $ 2.83 | $ 1.00 |
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- Definition Number of non-option equity instruments exercised by participants. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Number of shares under non-option equity instrument agreements for which rights to exercise lapsed. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Net number of non-option equity instruments granted to participants. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Change in the weighted average exercise price of options outstanding. No definition available.
|
X | ||||||||||
- Definition Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired. No definition available.
|